| Identification | Back Directory | [Name]
1Kg | [CAS]
2763617-39-4 | [Synonyms]
NT-0249
sodium (S)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)(N-(1-methyl-1H-pyrazol-4-yl)-N-((tetrahydrofuran-2-yl)methyl)sulfamoyl)amide | [Molecular Formula]
C22H28N5O4S.Na | [MOL File]
2763617-39-4.mol | [Molecular Weight]
481.55 |
| Hazard Information | Back Directory | [Uses]
NT-0249 is an orally active NLRP3 inhibitor. NT-0249 has anti-inflammatory activity[1] | [in vivo]
NT-0249 (100 mg/kg, orally, 3 times a day for 28 days) reduces systemic inflammation and astrocyte formation in mice in a pre-established obesity state[1].
| Animal Model: | Diet-Induced Obesity (DIO) in mice[1] | | Dosage: | 100 mg/kg | | Administration: | p.o. 3 times a day for 28 days | | Result: | Reduced inflammatory biomarkers sVCAM-1 and suPAR |
| [IC 50]
NLRP3 | [References]
[1] Thornton P, et al. Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796. J Pharmacol Exp Ther. 2024 Feb 15;388(3):813-826. DOI:10.1124/jpet.123.002013 |
|
|